Sleep apnea improvement: ZepBound is now FDA-approved for sleep apnea in people with obesity, as weight loss can ease symptoms like snoring and disrupted breathing
( ) 2
Canadian Access and Coverage Considerations Canadian patients face unique considerations when evaluating these medications
Patients should be cautious about any source claiming to supply retatrutide outside of a regulated clinical trial setting, as such products would not have undergone the rigorous safety and quality checks required for licensed medicines
For many individuals, starting with a simple foundation such as a multivitamin, protein support, and electrolytes is often enough to create a strong routine
Cochrane-standard systematic reviews have examined the randomized controlled trial data across multiple GLP-1 medications, and the weight of the published evidence supports the conclusion that in properly selected patients, GLP-1 receptor agonists produce clinically meaningful weight loss that exceeds what diet and exercise alone typically achieve without pharmacological support
